{"id":"biological-covid-19-convalescent-plasma","safety":{"commonSideEffects":[{"rate":"null","effect":"Thrombosis"},{"rate":"null","effect":"Allergic reactions"},{"rate":"null","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Convalescent plasma is derived from the blood of individuals who have recovered from COVID-19 and contains antibodies against the SARS-CoV-2 virus. These antibodies can provide passive immunity to individuals who are infected with COVID-19, helping to reduce the severity of symptoms and the risk of complications.","oneSentence":"COVID-19 convalescent plasma contains antibodies that help the body fight COVID-19 infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:24:16.406Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19 in adults and pediatric patients"}]},"trialDetails":[{"nctId":"NCT04411602","phase":"PHASE1","title":"Intermediate IND Severe Illness COVID-19 CP","status":"WITHDRAWN","sponsor":"Henry Ford Health System","startDate":"2020-04-07","conditions":"Severe Acute Respiratory Syndrome, COVID","enrollment":""},{"nctId":"NCT04973488","phase":"NA","title":"Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients","status":"COMPLETED","sponsor":"Novacescu Alexandru","startDate":"2020-07-25","conditions":"COVID-19 Pneumonia, COVID-19 Respiratory Infection, Acute Respiratory Failure","enrollment":38},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04516954","phase":"EARLY_PHASE1","title":"Convalescent Plasma for COVID-19 Patients","status":"COMPLETED","sponsor":"Vinmec Research Institute of Stem Cell and Gene Technology","startDate":"2020-08-01","conditions":"COVID 19","enrollment":4},{"nctId":"NCT04545047","phase":"","title":"Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2020-05-01","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":5044},{"nctId":"NCT04355897","phase":"EARLY_PHASE1","title":"CoVID-19 Plasma in Treatment of COVID-19 Patients","status":"COMPLETED","sponsor":"The Christ Hospital","startDate":"2020-04-28","conditions":"COVID 19","enrollment":22},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT04412486","phase":"EARLY_PHASE1","title":"COVID-19 Convalescent Plasma (CCP) Transfusion","status":"COMPLETED","sponsor":"Gailen D. Marshall Jr., MD PhD","startDate":"2020-06-01","conditions":"COVID-19","enrollment":86},{"nctId":"NCT04420988","phase":"","title":"Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients","status":"NO_LONGER_AVAILABLE","sponsor":"Rutgers, The State University of New Jersey","startDate":"","conditions":"COVID-19, SARS-CoV 2, SARS-CoV Infection","enrollment":""},{"nctId":"NCT05904067","phase":"NA","title":"A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-06-10","conditions":"COVID-19, Hematopoietic Stem Cell Transplantation","enrollment":72},{"nctId":"NCT04373460","phase":"PHASE2","title":"Convalescent Plasma to Limit SARS-CoV-2 Associated Complications","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-06-03","conditions":"SARS-CoV 2","enrollment":1225},{"nctId":"NCT05595538","phase":"EARLY_PHASE1","title":"Use of Multiple Doses of Convalescent Plasma in Mechanically Intubated Patients With COVID-19","status":"COMPLETED","sponsor":"Hospital Regional Dr. Rafael Estévez","startDate":"2020-06-06","conditions":"COVID-19","enrollment":30},{"nctId":"NCT04421404","phase":"PHASE2","title":"Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients","status":"COMPLETED","sponsor":"Priscilla Hsue, MD","startDate":"2020-06-09","conditions":"COVID-19, Sars-CoV2","enrollment":34},{"nctId":"NCT04539275","phase":"PHASE3","title":"VA CoronavirUs Research and Efficacy Studies-1","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2020-11-16","conditions":"COVID-19","enrollment":75},{"nctId":"NCT04397757","phase":"PHASE1","title":"COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-05-13","conditions":"COVID-19","enrollment":80},{"nctId":"NCT04366245","phase":"PHASE1, PHASE2","title":"Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection","status":"COMPLETED","sponsor":"Andalusian Network for Design and Translation of Advanced Therapies","startDate":"2020-04-23","conditions":"SARS-CoV 2","enrollment":72},{"nctId":"NCT04642014","phase":"NA","title":"Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness","status":"TERMINATED","sponsor":"Wroclaw Medical University","startDate":"2020-12-22","conditions":"COVID-19 Convalescent Plasma Treatment","enrollment":396},{"nctId":"NCT04388527","phase":"PHASE1","title":"COVID-19 Convalescent Plasma for Mechanically Ventilated Population","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-04-30","conditions":"Covid-19","enrollment":32},{"nctId":"NCT04721236","phase":"NA","title":"Early Use of Hyperimmune Plasma in COVID-19","status":"UNKNOWN","sponsor":"Catherine Klersy","startDate":"2020-11-19","conditions":"Covid19","enrollment":260},{"nctId":"NCT04432272","phase":"PHASE2","title":"ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)","status":"TERMINATED","sponsor":"Corewell Health East","startDate":"2020-07-16","conditions":"COVID-19, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections","enrollment":71},{"nctId":"NCT04649879","phase":"PHASE2, PHASE3","title":"Convalescent Plasma for Treatment of COVID-19","status":"COMPLETED","sponsor":"Joakim Dillner","startDate":"2020-12-03","conditions":"Covid19","enrollment":59},{"nctId":"NCT04390178","phase":"PHASE1, PHASE2","title":"Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)","status":"COMPLETED","sponsor":"Joakim Dillner","startDate":"2020-04-10","conditions":"COVID-19","enrollment":10},{"nctId":"NCT04384497","phase":"PHASE1, PHASE2","title":"Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study","status":"COMPLETED","sponsor":"Joakim Dillner","startDate":"2020-05-07","conditions":"COVID-19","enrollment":10},{"nctId":"NCT04353206","phase":"EARLY_PHASE1","title":"Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure","status":"TERMINATED","sponsor":"Noah Merin","startDate":"2020-06-27","conditions":"Covid-19, Sars-CoV2","enrollment":6},{"nctId":"NCT05046652","phase":"","title":"Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series","status":"COMPLETED","sponsor":"Maranatha Christian University","startDate":"2020-04-01","conditions":"Infectious Disease","enrollment":8},{"nctId":"NCT04873414","phase":"PHASE2, PHASE3","title":"Convalescent Plasma as Adjunct Therapy for COVID-19","status":"UNKNOWN","sponsor":"National Institute of Health Research and Development, Ministry of Health Republic of Indonesia","startDate":"2020-12-01","conditions":"COVID-19","enrollment":364},{"nctId":"NCT04374526","phase":"PHASE2, PHASE3","title":"Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-05-27","conditions":"Coronavirus Disease 2019 )COVID-19)","enrollment":29},{"nctId":"NCT04542967","phase":"PHASE2","title":"Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease","status":"COMPLETED","sponsor":"Hospital Central Militar","startDate":"2020-06-23","conditions":"Severe COVID-19 Disease","enrollment":150},{"nctId":"NCT04836260","phase":"PHASE3","title":"Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19","status":"UNKNOWN","sponsor":"University Hospital, Geneva","startDate":"2021-04-08","conditions":"Covid19, Immuno-Deficiency, Old Age; Debility","enrollment":100},{"nctId":"NCT04358211","phase":"","title":"Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19","status":"NO_LONGER_AVAILABLE","sponsor":"Nakhle Saba, MD","startDate":"","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04712344","phase":"PHASE2","title":"Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2021-01-18","conditions":"Severe COVID-19","enrollment":58},{"nctId":"NCT04542941","phase":"NA","title":"Assessment of Safety and Efficacy of CCP","status":"COMPLETED","sponsor":"Makerere University","startDate":"2020-06-16","conditions":"Covid19","enrollment":136},{"nctId":"NCT04634422","phase":"NA","title":"Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure","status":"UNKNOWN","sponsor":"Wladimir Szpirt","startDate":"2020-11-16","conditions":"Respiratory Failure, Renal Failure, Acute","enrollment":220},{"nctId":"NCT04565197","phase":"EARLY_PHASE1","title":"Convalescent Plasma Therapy for COVID-19 Patients","status":"UNKNOWN","sponsor":"Lahore General Hospital","startDate":"2020-05-01","conditions":"SARS-CoV Infection","enrollment":20},{"nctId":"NCT04332835","phase":"PHASE2, PHASE3","title":"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study","status":"COMPLETED","sponsor":"Universidad del Rosario","startDate":"2020-08-08","conditions":"Coronavirus, Coronavirus Infection","enrollment":92},{"nctId":"NCT04349410","phase":"PHASE2, PHASE3","title":"The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","status":"COMPLETED","sponsor":"The Camelot Foundation","startDate":"2020-04-11","conditions":"CoVid 19 Positive","enrollment":1800},{"nctId":"NCT04554992","phase":"PHASE1","title":"Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","startDate":"2020-03-20","conditions":"Covid19","enrollment":350},{"nctId":"NCT04383535","phase":"NA","title":"Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia","status":"COMPLETED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2020-05-15","conditions":"SARS Virus, SARS-CoV-2, COVID-19","enrollment":333},{"nctId":"NCT04392414","phase":"PHASE2","title":"Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease","status":"COMPLETED","sponsor":"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia","startDate":"2020-05-01","conditions":"COVID-19","enrollment":60},{"nctId":"NCT04375098","phase":"PHASE2","title":"Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2020-05-04","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2","enrollment":58},{"nctId":"NCT04338360","phase":"","title":"Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19","status":"APPROVED_FOR_MARKETING","sponsor":"Mayo Clinic","startDate":"","conditions":"COVID19","enrollment":""},{"nctId":"NCT04372368","phase":"","title":"Convalescent Plasma for the Treatment of Patients With COVID-19","status":"NO_LONGER_AVAILABLE","sponsor":"University of Colorado, Denver","startDate":"","conditions":"COVID-19, SARS-CoV 2","enrollment":""},{"nctId":"NCT04332380","phase":"PHASE2","title":"Convalescent Plasma for Patients With COVID-19: A Pilot Study","status":"COMPLETED","sponsor":"Universidad del Rosario","startDate":"2020-05-01","conditions":"Coronavirus, Coronavirus Infection","enrollment":10},{"nctId":"NCT04492501","phase":"NA","title":"Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan","status":"COMPLETED","sponsor":"UNICEF","startDate":"2020-04-01","conditions":"Covid19, Cytokine Release Syndrome, Critical Illness","enrollment":600},{"nctId":"NCT04395170","phase":"PHASE2, PHASE3","title":"Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.","status":"UNKNOWN","sponsor":"Lifefactors Zona Franca, SAS","startDate":"2020-09","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":75},{"nctId":"NCT04460547","phase":"","title":"Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic","status":"UNKNOWN","sponsor":"Qassim University","startDate":"2020-07-25","conditions":"COVID-19","enrollment":200},{"nctId":"NCT04425837","phase":"PHASE2, PHASE3","title":"Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19","status":"UNKNOWN","sponsor":"Fundación Santa Fe de Bogota","startDate":"2020-07","conditions":"Sars-CoV2, Covid-19","enrollment":236},{"nctId":"NCT04403477","phase":"PHASE2","title":"Convalescent Plasma Therapy in Severe COVID-19 Infection","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2020-05-20","conditions":"Covid19, Convalescence","enrollment":20},{"nctId":"NCT04385043","phase":"PHASE2, PHASE3","title":"Hyperimmune Plasma in Patients With COVID-19 Severe Infection","status":"UNKNOWN","sponsor":"University of Catanzaro","startDate":"2020-05-01","conditions":"COVID-19","enrollment":400},{"nctId":"NCT02333578","phase":"NA","title":"Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment","status":"UNKNOWN","sponsor":"Clinical Research Management, Inc.","startDate":"2014-11","conditions":"Ebola Virus Disease","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":116,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Biological: COVID-19 convalescent plasma","genericName":"Biological: COVID-19 convalescent plasma","companyName":"Nakhle Saba, MD","companyId":"nakhle-saba-md","modality":"Biologic","firstApprovalDate":"","aiSummary":"COVID-19 convalescent plasma contains antibodies that help the body fight COVID-19 infection. Used for Treatment of COVID-19 in adults and pediatric patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}